Once-Weekly Semaglutide Improves Body Composition in Spanish Obese Adults with Type 2 Diabetes: A 48-Week Prospective Real-Life Study
Journal of Clinical Medicine · 01.08.2025 · 14 (15) · 5434
DOI: 10.3390/jcm14155434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.08.2025. Verfasst von Irene Caballero-Mateos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Nutrition Department, Vithas Hospital, 41009 Sevilla, Spain. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
The objective of this study was to assess changes in body composition, with a specific focus on fat mass (FM) and fat-free mass (FFM), in obese adults with type 2 diabetes (T2D) treated with once-weekly (OW) subcutaneous (s.c.) semaglutide.
Methods
This was a single-center, 12-month, real-world, ambispective study (6-month prospective and 6-month retrospective). Body composition parameters were assessed via segmental multifrequency bioelectrical impedance analysis (SMF-BIA).
Results
A total of 117 patients with DM2, with a median age of 56 years, a median HbA1c level of 9.4%, and a median body weight of 102.5 kg, were included in the study. The median body weight, body fat mass, and visceral fat significantly decreased at 6 months, with values of −9.3, −7.5, and −1.8 kg, respectively. There were further reductions from 6 to 12 months, albeit at a slower rate. The median skeletal muscle mass significantly decreased at 6 months (−1.2 kg), although no further significant reductions were observed at 12 months.
Conclusions
OW s.c. semaglutide for 12 months significantly improved body composition parameters, mainly at the expense of fat mass loss, with the preservation of skeletal muscle mass. These changes are clinically meaningful, since they impact general metabolic health and are associated with improvements in metabolic control and clinical parameters associated with renal and CV risks, as well as presumable improvements in quality of life.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrinology and Nutrition Department, Vithas Hospital, 41009 Sevilla, Spain.
ORCID-Profile: Irene Caballero-Mateos, Beatriz González Aguilera
Zitieren
APA
Caballero-Mateos, I., Morales-Portillo, C., & González Aguilera, B. (2025). Once-Weekly Semaglutide Improves Body Composition in Spanish Obese Adults with Type 2 Diabetes: A 48-Week Prospective Real-Life Study. Journal of Clinical Medicine, 14(15), 5434. https://doi.org/10.3390/jcm14155434
Vancouver
Caballero-Mateos I, Morales-Portillo C, González Aguilera B. Once-Weekly Semaglutide Improves Body Composition in Spanish Obese Adults with Type 2 Diabetes: A 48-Week Prospective Real-Life Study. Journal of Clinical Medicine. 2025;14(15):5434. doi:10.3390/jcm14155434
BibTeX
@article{CaballeroMateos2025,
author = {Caballero-Mateos, Irene and Morales-Portillo, Cristóbal and González Aguilera, Beatriz},
title = {Once-Weekly Semaglutide Improves Body Composition in Spanish Obese Adults with Type 2 Diabetes: A 48-Week Prospective Real-Life Study},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {15},
pages = {5434},
doi = {10.3390/jcm14155434}
}
EUVIMED